Literature DB >> 9281318

Structural determinants for the intracellular localization of the isozymes of mammalian hexokinase: intracellular localization of fusion constructs incorporating structural elements from the hexokinase isozymes and the green fluorescent protein.

D Sui1, J E Wilson.   

Abstract

Fusion constructs incorporating structural elements from mammalian isozymes of hexokinase, Types I-IV, in frame with sequence encoding the green fluorescent protein (GFP) have been made and expressed in hexokinase-deficient M + R 42 cells. Fusion proteins incorporating catalytically active regions from the Type II isozyme, or the entire Type IV sequence, were expressed in catalytically active form. The intracellular localization of the fusion proteins was determined using confocal microscopy. Fusion proteins including the N-terminal halves of the Type I or Type II isozymes were targeted to mitochondria, while the N-terminal half of the Type III isozyme did not confer mitochondrial targeting. The mitochondrial targeting signal was represented by the hydrophobic sequence at the extreme N-termini ("binding domain") of the Type I and Type II isozymes. Inclusion of the binding domain from the Type I isozyme was sufficient to confer mitochondrial binding on GFP itself as well as on constructs including the N-terminal half of Type III hexokinase. However, the Type I hexokinase binding domain was not sufficient to cause mitochondrial targeting of a construct containing the Type IV sequence. These results suggest that, although the binding domain is critical for mitochondrial targeting, other interactions involving an adjacent structure might also play a role. Fusion proteins including the N-terminal half of Type I hexokinase became dissociated from mitochondria under conditions favorable for accumulation of intracellular Glc-6-P. The 2-deoxy analog was much less effective than Glc in causing mitochondrial dissociation of the fusion construct, in accord with previous studies showing 2-deoxy-Glc-6-P to be much less effective than Glc-6-P at promoting release of Type I hexokinase from mitochondria. Dissociation, induced by formation of Glc-6-P or 2-deoxy-Glc-6-P, did not occur with the fusion protein including only the binding domain of Type I hexokinase. This is consistent with previous studies indicating that Glc-6-P-dependent dissociation results from binding of this ligand to a site in the N-terminal half of the enzyme, but which is not likely to be present in the small segment represented by the binding domain. These studies demonstrate the usefulness of this approach in defining structural elements involved in targeting hexokinase isozymes to specific subcellular locations and modulation of that intracellular location by perturbations of metabolic status.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281318     DOI: 10.1006/abbi.1997.0241

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  36 in total

1.  The glutamate transporter, GLAST, participates in a macromolecular complex that supports glutamate metabolism.

Authors:  Deborah E Bauer; Joshua G Jackson; Elizabeth N Genda; Misty M Montoya; Marc Yudkoff; Michael B Robinson
Journal:  Neurochem Int       Date:  2012-01-28       Impact factor: 3.921

2.  Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury.

Authors:  Rongxue Wu; Kirsten M Smeele; Eugene Wyatt; Yoshihiko Ichikawa; Otto Eerbeek; Lin Sun; Kusum Chawla; Markus W Hollmann; Varun Nagpal; Sami Heikkinen; Markku Laakso; Kentaro Jujo; J Andrew Wasserstrom; Coert J Zuurbier; Hossein Ardehali
Journal:  Circ Res       Date:  2010-11-11       Impact factor: 17.367

Review 3.  The role of VDAC in cell death: friend or foe?

Authors:  Kyle S McCommis; Christopher P Baines
Journal:  Biochim Biophys Acta       Date:  2011-10-28

Review 4.  Uncovering the role of VDAC in the regulation of cell life and death.

Authors:  Varda Shoshan-Barmatz; Nurit Keinan; Hilal Zaid
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

Review 5.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

Review 6.  Hexokinases and cardioprotection.

Authors:  Guillaume Calmettes; Bernard Ribalet; Scott John; Paavo Korge; Peipei Ping; James N Weiss
Journal:  J Mol Cell Cardiol       Date:  2014-09-26       Impact factor: 5.000

7.  Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.

Authors:  Jeffrey C Rathmell; Casey J Fox; David R Plas; Peter S Hammerman; Ryan M Cinalli; Craig B Thompson
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 8.  MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx.

Authors:  Demet Candas; Jian Jian Li
Journal:  Antioxid Redox Signal       Date:  2013-06-08       Impact factor: 8.401

9.  Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition.

Authors:  David J Roberts; Valerie P Tan-Sah; Eric Y Ding; Jeffery M Smith; Shigeki Miyamoto
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

10.  Regulation and cytoprotective role of hexokinase III.

Authors:  Eugene Wyatt; Rongxue Wu; Wael Rabeh; Hee-Won Park; Mohsen Ghanefar; Hossein Ardehali
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.